Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | HRH1 | P35367 | 3/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11891459 | 0.82 | SIGMAR1 (0.50) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| SCHEMBL3874745 | 0.79 | HTR2A (0.61) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| SCHEMBL10863210 | 0.79 | HTR2A (0.52) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| SCHEMBL9874718 | 0.75 | HTR2A (0.57) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| SCHEMBL11827705 | 0.73 | ALDH1A1 (0.49) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| Opipramol SCHEMBL29414094 | 0.73 | DRD2 (1.00) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| Opipramol SCHEMBL49841 | 0.73 | DRD2 (1.00) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| Opipramol SCHEMBL30020862 | 0.72 | CYP3A4 (1.00) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| Opipramol SCHEMBL366168 | 0.72 | CYP3A4 (1.00) | HTR2AHRH1CHRM2CHRM1DRD2 | |
| Opipramol SCHEMBL16416273 | 0.72 | DRD2 (0.97) | HTR2AHRH1CHRM2CHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10376522-B2 | Triarylmethane analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170000801-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | THE US GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2017-01-05 | — | — | US | disclosed |
| US-20170000801-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | THE US GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2017-01-05 | — | — | US | disclosed |
| US-20100189762-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189762-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2009088838-A2 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176745-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176745-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000801-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | TK2, TXNRD2, TXN2 | HTR2A 1488/4885HRH1 1219/4885CHRM2 4192/4885 |
| US-20090176745-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | TK2, TXNRD2, TXN2 | HTR2A 1488/4885HRH1 1219/4885CHRM2 4192/4885 |
| US-10376522-B2 | Triarylmethane analogs and their use in treating cancers | TK2, TXNRD2, TXN2 | HTR2A 1481/4885HRH1 1252/4885CHRM2 4197/4885 |
| US-20100189762-A1 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS | TK2, TXNRD2, TXN2 | HTR2A 1488/4885HRH1 1219/4885CHRM2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.